Insight Molecular Diagnostics, Inc. (IMDX)
4.14
+0.13
(+3.24%)
USD |
NASDAQ |
Sep 22, 16:00
4.115
-0.02
(-0.60%)
After-Hours: 20:00
Insight Molecular Diagnostics Total Liabilities (Quarterly) : 50.74M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 50.74M |
| March 31, 2026 | 51.12M |
| December 31, 2025 | 57.22M |
| September 30, 2025 | 53.13M |
| June 30, 2025 | 49.42M |
| March 31, 2025 | 50.14M |
| December 31, 2024 | 47.36M |
| September 30, 2024 | 60.50M |
| June 30, 2024 | 52.02M |
| March 31, 2024 | 54.05M |
| December 31, 2023 | 49.30M |
| September 30, 2023 | 39.10M |
| June 30, 2023 | 39.22M |
| March 31, 2023 | 39.34M |
| December 31, 2022 | |
| September 30, 2022 | 75.41M |
| June 30, 2022 | 82.95M |
| March 31, 2022 | 89.31M |
| December 31, 2021 | 94.35M |
| September 30, 2021 | 68.99M |
| June 30, 2021 | 74.72M |
| March 31, 2021 | 22.68M |
| Date | Value |
|---|---|
| December 31, 2020 | 21.94M |
| September 30, 2020 | 23.14M |
| June 30, 2020 | 23.86M |
| March 31, 2020 | 22.88M |
| December 31, 2019 | 9.021M |
| September 30, 2019 | 3.435M |
| June 30, 2019 | 4.161M |
| March 31, 2019 | 3.49M |
| December 31, 2018 | 6.095M |
| September 30, 2018 | 5.382M |
| June 30, 2018 | 5.35M |
| March 31, 2018 | 6.56M |
| December 31, 2017 | 5.813M |
| September 30, 2017 | 6.201M |
| June 30, 2017 | 6.502M |
| March 31, 2017 | 6.401M |
| December 31, 2016 | 4.585M |
| September 30, 2016 | 4.179M |
| June 30, 2016 | 2.957M |
| March 31, 2016 | 2.752M |
| December 31, 2015 | 2.314M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Perspective Therapeutics, Inc. | 68.16M |
| Agenus, Inc. | 378.54M |
| Amgen, Inc. | 83.95B |
| Anika Therapeutics, Inc. | 46.19M |
| BioCryst Pharmaceuticals, Inc. | 1.012B |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 29.44M |
| Shareholders Equity (Quarterly) | -21.30M |
| Debt to Equity Ratio | -0.1232 |
| Current Ratio | 1.997 |
| Net Debt Paydown Yield | 0.09% |